GlassScriptPhysician profile
Maria T Rivero
NPI 1770524233
$3,390.13
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $386 · 2021: $613 · 2022: $859 · 2023: $785 · 2024: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.96 |
| Education | $119.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $521.33 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Mayne Pharma Commercial LLC | $409.49 | 2021-2023 | |
| Astellas Pharma US INC | $364.17 | 2022-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $348.87 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $227.16 | 2019-2023 | |
| Medtronic, INC. | $168.86 | 2022-2023 | Truclear |
| Lupin INC. | $146.92 | 2019-2021 | |
| Evofem Biosciences, INC. | $141.25 | 2021-2022 | |
| Hologic Sales and Service, LLC | $117.35 | 2019-2021 | |
| Millicent US INC | $107.23 | 2020-2024 | Femring, Intrarosa |
| Shield Therapeutics INC | $99.54 | 2023-2024 | Accrufer |
| Myovant Sciences INC. | $85.05 | 2021-2022 | |
| Exeltis, USA INC. | $81.08 | 2021-2023 | Slynd |
| Organon LLC | $64.65 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $57.38 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $57.20 | 2022 | |
| Avion Pharmaceuticals | $52.80 | 2019-2021 | |
| Aspira Women'S Health INC | $44.49 | 2019-2023 | Ova1 |
| Amag Pharmaceuticals, INC. | $31.28 | 2019-2020 | |
| Allergan, INC. | $30.57 | 2019-2020 | |
| Covidien LP | $29.93 | 2019 | |
| Therapeuticsmd, INC. | $25.62 | 2019 | |
| Mylan Pharmaceuticals INC. | $23.84 | 2022 | |
| Kyowa Kirin, INC. | $21.91 | 2023 | Crysvita |
| Acessa Health INC. | $21.70 | 2019 | |
| Biogen, INC. | $20.61 | 2024 | |
| Smith+Nephew, INC. | $19.34 | 2019 | |
| Avanos Medical | $16.09 | 2019 | |
| Sage Therapeutics, LLC | $14.65 | 2021 | |
| Medicem INC. | $14.26 | 2020 | |
| Myriad Women'S Health, INC. | $13.49 | 2023 | Myrisk |
| Ascend Therapeutics US, LLC | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Rivero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.